Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...
HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...
If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...
Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that ...
"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...
William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating on January 14.Stay Ahead of the ...
Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...
Its first treatment, Casgevy, earned approval from the Food and Drug Administration (FDA) to treat sickle cell disease in December 2023. Last January, the FDA approved Casgevy again to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback